First-order effects

• Big Health gains roughly a doubling-plus of its prior total raised ($54.3M after the Series B), giving it capital to scale Sleepio and Daylight distribution while rivals like Cerebral deploy far larger war chests.
• SoftBank Vision Fund 2 now holds three named digital mental health positions — Pear Therapeutics, Cerebral, and Big Health — concentrating its bets on app-based behavioral care within a fund already investing at twice its predecessor's pace.

Second-order effects

• Big Health's no-clinician model puts it on a collision course with consumer wellness players like Calm, which raised the same $75M amount at a $2B valuation for meditation and sleep content — employers buying sleep benefits must now choose between content libraries and clinical-grade automation.
• Vision Fund 2's cadence of large mental health checks forces other investors in the space (Oak HC/FT led Cerebral's earlier round) to either mark up follow-ons or cede pricing power on later-stage deals.

Third-order effects

• If the pattern holds, digital mental health splits into two capital-intensive camps — fully automated programs like Big Health's versus clinician-and-medication platforms like Cerebral's — with SoftBank effectively underwriting both sides of the split.
• The concentration of mega-rounds among a handful of SoftBank-backed players points toward a market where scale of distribution, not clinical approach alone, determines which apps reach employer and payer channels.